The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 15, 2015
Filed:
Jun. 13, 2012
Applicant:
David S. Garvey, Dover, MA (US);
Inventor:
David S. Garvey, Dover, MA (US);
Assignee:
Bikam Pharmaceuticals, Inc., Lexington, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 25/06 (2006.01); C07D 333/16 (2006.01); C07D 333/22 (2006.01); C07D 307/42 (2006.01); C07D 307/46 (2006.01); C07C 33/14 (2006.01); C07C 33/34 (2006.01); C07C 33/50 (2006.01); C07C 43/23 (2006.01); C07C 255/53 (2006.01); C07C 255/56 (2006.01); C07C 259/18 (2006.01); C07C 25/18 (2006.01); C07C 25/13 (2006.01); C07C 49/792 (2006.01); C07C 49/813 (2006.01); C07C 49/84 (2006.01);
U.S. Cl.
CPC ...
C07C 25/06 (2013.01); C07C 25/13 (2013.01); C07C 25/18 (2013.01); C07C 33/14 (2013.01); C07C 33/34 (2013.01); C07C 33/50 (2013.01); C07C 43/23 (2013.01); C07C 49/792 (2013.01); C07C 49/813 (2013.01); C07C 49/84 (2013.01); C07C 255/53 (2013.01); C07C 255/56 (2013.01); C07C 259/18 (2013.01); C07D 307/42 (2013.01); C07D 307/46 (2013.01); C07D 333/16 (2013.01); C07D 333/22 (2013.01); C07C 2101/14 (2013.01);
Abstract
Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.